Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 6NIH 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 13CNS 7Head & Neck 4Gastrointestinal 4Sarcoma 3Gynecologic 2Genitourinary 2Thoracic 1Dermatologic 1

Conditions

Endometrial Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Carboplatin 62Paclitaxel 61Specimen Handling 37Cisplatin 37Taxes 35Magnetic Resonance Spectroscopy 31Bevacizumab 30Immunoglobulin G 23Disulfides 23Biopsy 22Cyclophosphamide 19aldesleukin 17Topotecan 16Brachytherapy 16Radiotherapy 15Gemcitabine 15veliparib 14Oxaliplatin 13Doxorubicin 13temsirolimus 12fludarabine 12Platinum 12Docetaxel 121,2-diaminocyclohexaneplatinum II citrate 12olaparib 11liposomal doxorubicin 10cediranib 10Sirolimus 10Radiation 9Nivolumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Lapatinib × Gynecologic × Clear all
NCT00096447 2019-07-24

Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Completed
31 enrolled 13 charts
Gynecologic

Endometrial Neoplasms

NCT00113373 2019-07-24

Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer

National Cancer Institute (NCI)

Phase 2 Completed
28 enrolled 11 charts
Gynecologic

Carcinoma, Ovarian Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡